C R Bard Inc (BCR) Shares Sold by Foster & Motley Inc.

Foster & Motley Inc. lowered its stake in shares of C R Bard Inc (NYSE:BCR) by 6.0% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 3,464 shares of the medical instruments supplier’s stock after selling 223 shares during the period. Foster & Motley Inc.’s holdings in C R Bard were worth $1,147,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of BCR. Monroe Bank & Trust MI lifted its stake in C R Bard by 65.6% during the 3rd quarter. Monroe Bank & Trust MI now owns 447 shares of the medical instruments supplier’s stock valued at $100,000 after acquiring an additional 177 shares during the period. Patten Group Inc. lifted its stake in C R Bard by 66.0% during the 3rd quarter. Patten Group Inc. now owns 556 shares of the medical instruments supplier’s stock valued at $106,000 after acquiring an additional 221 shares during the period. Valeo Financial Advisors LLC bought a new position in C R Bard during the 3rd quarter valued at about $170,000. Glovista Investments LLC bought a new position in C R Bard during the 2nd quarter valued at about $221,000. Finally, Fieldpoint Private Securities LLC bought a new position in C R Bard during the 3rd quarter valued at about $234,000. Institutional investors and hedge funds own 79.11% of the company’s stock.

In other C R Bard news, VP John A. Deford sold 14,107 shares of the business’s stock in a transaction that occurred on Wednesday, December 20th. The stock was sold at an average price of $333.48, for a total value of $4,704,402.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David M. Barrett sold 3,344 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $327.31, for a total value of $1,094,524.64. The disclosure for this sale can be found here. Insiders sold 114,602 shares of company stock valued at $38,193,867 over the last three months. 0.80% of the stock is currently owned by corporate insiders.

Several research firms have issued reports on BCR. Zacks Investment Research upgraded shares of C R Bard from a “hold” rating to a “buy” rating and set a $372.00 target price on the stock in a research note on Tuesday, December 26th. ValuEngine cut shares of C R Bard from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Barclays increased their price objective on shares of C R Bard from $245.00 to $337.00 and gave the stock an “equal weight” rating in a research note on Monday, November 6th. Cowen reiterated a “hold” rating and issued a $317.00 price objective on shares of C R Bard in a research note on Friday, November 3rd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of C R Bard in a research note on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $311.43.

C R Bard Inc (NYSE BCR) opened at $331.24 on Tuesday. C R Bard Inc has a one year low of $222.42 and a one year high of $337.73. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.57. The firm has a market cap of $24,140.00, a P/E ratio of 43.64, a PEG ratio of 2.53 and a beta of 0.52.

C R Bard (NYSE:BCR) last issued its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.96 by $0.06. C R Bard had a net margin of 9.51% and a return on equity of 19.39%. The firm had revenue of $989.80 million for the quarter, compared to analysts’ expectations of $990.64 million. During the same quarter in the prior year, the business earned $2.64 EPS. The business’s quarterly revenue was up 5.1% on a year-over-year basis. research analysts expect that C R Bard Inc will post 11.89 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “C R Bard Inc (BCR) Shares Sold by Foster & Motley Inc.” was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.com-unik.info/2018/01/23/c-r-bard-inc-bcr-shares-sold-by-foster-motley-inc.html.

About C R Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C R Bard Inc (NYSE:BCR).

Institutional Ownership by Quarter for C R Bard (NYSE:BCR)

Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit